Everything drug pricing and policy, every day
And the House Oversight Committee is taking a swing at PBMs and their GPOs
And a few words on public health in light of yesterday’s news
And a Novartis exec explains the link between the UK’s drug reimbursement policies and the shrinking investment in the country
And a Trump advisor offers a vision for the White House's thinking around efforts to “secure America’s medicines”
Beyond that, it's mostly quick hits on this summer Friday, with more on tariffs, MFN, and formulary coverage
And United makes a list of all of the reputational risks that the company is facing right now
And a visualization that maps how Amazon’s effort to dominate the world (or, at least, retail pharmacy) is going
And new research confirms a longstanding truth: 340B hospitals spend way more per patient on meds than their non-340B peers
And Ozempic officially enters the cash-pay market
